Arrhythmias: antiarrhythmic agents.
Arrhythmias and sudden cardiac death resulting from ventricular tachycardia/fibrillation are important public health issues of this decade. Complexities surrounding the subject, plus a relatively experimental and toxic therapeutic armamentarium with poorly defined end points, have largely limited the field to the specialized cardiologist. Recent studies, however, have served to identify those at risk as a result of their dysrhythmia,, and given the improved methods for detection and monitoring and a host of potent new antiarrhythmic drugs, interest in the area is certain to broaden. Inasmuch as initial presentation and follow-up often lie within the realm of the family physician or generalist, an understanding and update of this important subject is in order.
R J
RJ
Herman
Cardiol Clin. 1984 Feb;2(1):35-46
6443563
Postgrad Med. 1985 Sep 15;78(4):28-37
2412217
Curr Probl Cardiol. 1986 Apr;11(4):177-240
3086035
N Engl J Med. 1986 Jul 3;315(1):41-5
3086724
N Engl J Med. 1985 Jan 24;312(4):193-7
2578212
Chest. 1985 Oct;88(4):618-24
3930162
N Engl J Med. 1987 Jan 1;316(1):29-34
3537793
N Engl J Med. 1986 Jul 3;315(1):36-41
3520324
Am Heart J. 1986 Jun;111(6):1162-76
2424297